Buch, Englisch, 357 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 717 g
Buch, Englisch, 357 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 717 g
Reihe: Cancer Drug Discovery and Development
ISBN: 978-3-319-78153-2
Verlag: Springer International Publishing
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases.
The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
Weitere Infos & Material
Chapter 1. “Introduction: Motivations for Next-Generation ADCs” -Marc Damelin
Chapter 2. “Combining ADCs with Immuno-oncology Agents” -- Philipp Müller, Jonathan Rios-Doria, Jay Harper and Anthony Cao
Chapter 3. “Improving the Safety Profile of ADCs” -- MagaliGuffroy, HadiFalahatpisheh and Martin Finkelstein
Chapter 4. “Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development” -- Aman P. Singh and Dhaval K. ShahChapter 5.“Regulatory Considerations and Companion Diagnostics” – Elizabeth VanAlphen and Omar Perez
Chapter 6. “ADC Process Development and Manufacturing” – Olivier Marcq
Chapter 7. “HER2-Targeted ADCs: At the forefront of ADC technology development” – Kevin J. Hamblett
Chapter 8. “Next generation payloads for ADCs” – L. Nathan TumeyChapter 9.“Delivering more payload: High DAR ADCs” - Natalya Bodyak and Alexander V.Yurkovetskiy
Chapter 10.“Site-Specific Antibody Drug Conjugates” – Feng Tian, Dowdy Jackson and Yun Bai
Chapter 11. “Bispecific and Biparatopic Antibody-Drug Conjugates” -- Frank Comer, Changshou Gao and Steve Coats
Chapter 12. “Targeting drug conjugates to the tumor microenvironment: Probody Drug Conjugates” -- Jack Lin and Jason Sagert
Chapter 13.“Antibody-Drug Conjugates: Targeting the Tumor Microenvironment” – Alberto Dal Corso, SamueleCazzamalli and Dario Neri
Chapter 14. “Next Horizons: ADCs Beyond Oncology” -- Shan Yu, Andrew Lim and Matthew S. Tremblay
